Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 970Neoplasms 767Carcinoma, Non-Small-Cell Lung 750Prostatic Neoplasms 577Colorectal Neoplasms 503Lung Neoplasms 447Neoplasm Metastasis 408Multiple Myeloma 376Leukemia, Myeloid, Acute 358Ovarian Neoplasms 311Pancreatic Neoplasms 306Melanoma 275Squamous Cell Carcinoma of Head and Neck 259Recurrence 248Carcinoma, Hepatocellular 233Glioblastoma 225Brain Neoplasms 221Head and Neck Neoplasms 202Triple Negative Breast Neoplasms 200Carcinoma, Renal Cell 200Lymphoma 192Precursor Cell Lymphoblastic Leukemia-Lymphoma 191Stomach Neoplasms 189Endometrial Neoplasms 179Lymphoma, Non-Hodgkin 175Sarcoma 169Glioma 168Uterine Cervical Neoplasms 167Lymphoma, Large B-Cell, Diffuse 160Hematologic Neoplasms 159

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Jaw Neoplasms × 90 days × Clear all
NCT07552558 2026-06-03

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Washington University School of Medicine

Phase 1/2 Not yet recruiting
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Jaw Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡